Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Unknown 5Recruiting 3Not yet recruiting 2Completed 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Carcinoma, Hepatocellular 20Nasopharyngeal Carcinoma 12Triple Negative Breast Neoplasms 11Esophageal Neoplasms 11Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 10Sarcoma 7Squamous Cell Carcinoma of Head and Neck 6Lung Neoplasms 6Uterine Cervical Neoplasms 5Melanoma 5Hodgkin Disease 5Recurrence 4Colorectal Neoplasms 4Breast Neoplasms 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Neoplasm Metastasis 3NSCLC 3Advanced Gastric Cancer 3Respiratory Tract Diseases 2Rectal Neoplasms 2Osteosarcoma 2Neoplasms 2Nasopharyngeal Neoplasms 2Metastatic Gastric Adenocarcinoma 2Lymphoma, Extranodal NK-T-Cell 2Lung Diseases 2

Interventions

Cisplatin 44Paclitaxel 21Radiotherapy 20Brachytherapy 19Carboplatin 18Bevacizumab 7Drug Therapy 6camrelizumab 5toripalimab 4nimotuzumab 4Radiation 4Neoadjuvant Therapy 4Gemcitabine 4tislelizumab 3sintilimab 3pembrolizumab 3apatinib 3Vaccines 3TP protocol 3Surgical Procedures, Operative 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3nedaplatin 2fludarabine 2endostar protein 2anlotinib 2Topotecan 2Surveys and Questionnaires 2Sentinel Lymph Node Biopsy 2Radiotherapy, Intensity-Modulated 2Mindfulness 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Uterine Cervical Neoplasms × camrelizumab × Clear all
NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
265 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT05311566 2022-04-13

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Peking Union Medical College Hospital

Phase 2 Unknown
92 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT05151549 2021-12-09

A Study of Carilizumab Combined With Concurrent Chemoradiotherapy

Hunan Cancer Hospital

Phase 2 Unknown
46 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT04974944 2021-10-01

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

Sun Yat-sen University

Phase 2 Unknown
172 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT04974827 2021-08-10

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

Hunan Cancer Hospital

Phase 2 Unknown
46 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡